AIN
Enabling Exosome Therapy

Enabling Exosome Therapy

location_on York & Humb ,  United Kingdom

The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Investors should carry out their own due diligence and take professional advice where necessary.

Short Summary

Mesenbio is developing new arthritis medicines using exosomes – tiny natural messengers from stem cells that calm inflammation and repair tissue. Our unique platform also provides pharma companies with consistent tools for drug discovery.

Highlights

  • Proprietary stem cell platform proven for consistent, scalable exosomes
  • Candidate MEV-N01 shows efficacy in preclinical rheumatoid arthritis models
  • £1.4M raised (Innovate UK + private)
  • Revenue potential from pharma licensing of FT-01 exosome platform
  • Blockbuster potential for MEV-N01 as a first-in-class arthritis therapy

Overview

Target £400,000
Minimum £10,000
Investment Raised £0
Previous Rounds £1,500,000
Stage Pre-Startup/R&D
Investor Role Any

Ask a question
Got a question about this project?

Similar Projects

This promotion is exempt from the general restriction in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds it is made exclusively to ‘investment professionals’ within the meaning of Article 19 of the Financial Services and Markets Act (Financial Promotion) Order 2005 (FinProm); persons believed on reasonable grounds to be ‘certified high net worth individuals’ within the meaning of Article 48 FinProm; persons who are ‘certified sophisticated investors’ within the meaning of Article 50 FinProm; and persons who are ‘self-certified sophisticated investors’ within the meaning of Article 50A FinProm.

If you are in any doubt about the investment to which this email relates, you are strongly recommended to consult an appropriately authorised financial adviser qualified to give advice in relation to investment. This investment opportunity will not necessarily be suitable for all recipients of this email. Applications to subscribe for shares will only be accepted at the company's discretion from persons eligible to invest.